Literature DB >> 8939750

Structures of the extracellular domain of the type I tumor necrosis factor receptor.

J H Naismith1, T Q Devine, T Kohno, S R Sprang.   

Abstract

BACKGROUND: Tumor necrosis factor (TNF) is a powerful cytokine that is involved in immune and pro-inflammatory responses. Two TNF receptors that belong to the cysteine-rich low affinity nerve growth factor receptor family (TNF-R1 and TNF-R2) are the sole mediators of TNF signalling. Signalling is thought to occur when a trimer of TNF binds to the extracellular domains of two or three receptor molecules, which permits aggregation and activation of the cytoplasmic domains. The complex is then internalized within an endocytic vesicle, whereupon it dissociates at low pH. Structure of the soluble extracellular domain of the receptor (sTNF-R1) both in the unliganded and TNF-bound state have previously been determined. In both instances, the fourth subdomain of the receptor was found to be partly disordered. In the unliganded state at pH 7.5, the extracellular domain forms two distinct types of dimer, parallel and antiparallel; the antiparallel dimer occludes the TNF-binding.
RESULTS: We have determined the structure of sTNF-R1 in two crystal forms in high salt at pH 3.7. The orthorhombic crystals diffract to 1.85 ånd the entire polypeptide is well ordered. In contrast, the C-terminal 32 residues are disordered in the hexagonal crystals. In the orthorhombic form, these residues exhibit a topology and disulphide connectivity that differs from the other three cysteine-rich domains in the molecule. In both forms, the interface is considerably more extensive than that used in complex formation with LTalpha. This 'low pH' dimer is different from both of the dimers observed in crystals grown at pH 7.5.
CONCLUSIONS: The occurrence of the antiparallel dimers in both low pH crystal forms suggest that they are not an artefact of crystal packing. Such dimers may form in the low pH environment of the endosome. Because the dimer contact surface occludes the TNF-binding site, formation of this dimer would dissociate the TNF-receptor complex within the endosome. Three of the four cysteine-rich domains of TNF-R1 are constructed from two distinct structural modules, termed A1 and B2. The fourth subdomain comprises an A1 module followed by an unusual C2 module. Although the orientation of these modules with respect to each other is sensitive to crystal packing, ligand binding, pH and ionic strength, the modules are structurally well conserved between and within the known sTNF-R1 structures.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8939750     DOI: 10.1016/s0969-2126(96)00134-7

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  37 in total

1.  Structure-based analysis of the herpes simplex virus glycoprotein D binding site present on herpesvirus entry mediator HveA (HVEM).

Authors:  Sarah A Connolly; Daniel J Landsburg; Andrea Carfi; Don C Wiley; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.

Authors:  I Aksentijevich; J Galon; M Soares; E Mansfield; K Hull; H H Oh; R Goldbach-Mansky; J Dean; B Athreya; A J Reginato; M Henrickson; B Pons-Estel; J J O'Shea; D L Kastner
Journal:  Am J Hum Genet       Date:  2001-07-06       Impact factor: 11.025

3.  The interaction of neurotrophins with the p75NTR common neurotrophin receptor: a comprehensive molecular modeling study.

Authors:  I L Shamovsky; G M Ross; R J Riopelle; D F Weaver
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

4.  Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death.

Authors:  Lisa M Sedger; Sarah R Osvath; Xiao-Ming Xu; Grace Li; Francis K-M Chan; John W Barrett; Grant McFadden
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 5.  Death receptors and caspases: role in lymphocyte proliferation, cell death, and autoimmunity.

Authors:  Sabine Adam-Klages; Dieter Adam; Ottmar Janssen; Dieter Kabelitz
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling.

Authors:  Francis Ka-Ming Chan
Journal:  Cytokine       Date:  2007-04-20       Impact factor: 3.861

7.  Crystallization and preliminary X-ray analysis of mouse RANK and its complex with RANKL.

Authors:  Thomas S Walter; Changzhen Liu; Peng Huang; Shiqian Zhang; Lucy R Wedderburn; Bin Gao; Raymond J Owens; David I Stuart; Peifu Tang; Jingshan Ren
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-05-22

8.  Variants of Osteoprotegerin Lacking TRAIL Binding for Therapeutic Bone Remodeling in Osteolytic Malignancies.

Authors:  Jerome T Higgs; John S Jarboe; Joo Hyoung Lee; Diptiman Chanda; Carnellia M Lee; Champion Deivanayagam; Selvarangan Ponnazhagan
Journal:  Mol Cancer Res       Date:  2015-01-30       Impact factor: 5.852

9.  A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss.

Authors:  Kazuhiro Aoki; Hiroaki Saito; Cecile Itzstein; Masaji Ishiguro; Tatsuya Shibata; Roland Blanque; Anower Hussain Mian; Mariko Takahashi; Yoshifumi Suzuki; Masako Yoshimatsu; Akira Yamaguchi; Pierre Deprez; Patrick Mollat; Ramachandran Murali; Keiichi Ohya; William C Horne; Roland Baron
Journal:  J Clin Invest       Date:  2006-05-04       Impact factor: 14.808

10.  Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.

Authors:  Akihiro Hasegawa; Xin Cheng; Kiichi Kajino; Alan Berezov; Kaoru Murata; Toshinori Nakayama; Hideo Yagita; Ramachandran Murali; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.